Abstract 1881O
Background
In the phase 1 LITESPARK-001 study of the HIF-2α inhibitor belzutifan for ccRCC, the MTD was not reached for dosages up to 240 mg per day, and the RP2D was 120 mg QD based on PD, PK, and safety. The phase 2 LITESPARK-013 study (NCT04489771) examined if a higher belzutifan dose could improve efficacy while maintaining an acceptable safety profile.
Methods
Pts with advanced ccRCC, measurable disease per RECIST v1.1, ≤3 prior systemic regimens for advanced ccRCC including an anti–PD-1/L1 agent, and disease progression during or after an anti–PD-1/L1 agent were randomly assigned 1:1 to belzutifan 120 mg or 200 mg QD. Pts were stratified by IMDC risk score (0 vs 1-2 vs 3-6) and number of prior TKI therapies for advanced ccRCC (0 vs 1 vs 2-3). Primary end point was ORR per RECIST v1.1 by blinded independent central review. Secondary end points included DOR, PFS, OS, safety, and PK. Database cutoff was February 10, 2023.
Results
154 pts were enrolled (120 mg: n=76; 200 mg: n=78). Baseline characteristics were well balanced between arms. Median follow-up was 20.1 months (range 14.8-28.4). ORR was 23.7% (18 PR) vs 23.1% (4 CR; 14 PR) for the 120 mg and 200 mg arms, respectively (P=0.5312; −0.5% [95% CI, −14.0 to 12.9] using the Miettinen-Nurminen method stratified by IMDC risk). PFS (median 7.3 vs 9.1 months; HR 0.94 [95% CI 0.63-1.40]) and OS (medians not reached; HR 1.11 [95% CI, 0.65-1.90]) did not differ between arms. Median DOR was not reached for the 120 mg arm (range 2.6+ to 16.1+) and was 16.1 mo (2.1+ to 23.5+) for the 200 mg arm; 64.7% and 51.3% of pts had ongoing responses ≥15 mo, respectively. 142 pts had a treatment-related AE (TRAE; 70 [92.1%] with 120 mg; 72 [92.3%] with 200 mg]. 2 pts (2.6%) in the 120 mg arm and 7 (9.0%) in the 200 mg arm discontinued treatment due to a TRAE. Treatment-related anemia (81.6% with 120 mg and 83.3% with 200 mg) and hypoxia (23.7% with 120 mg and 26.9% with 200 mg) was similar between arms.
Conclusions
The efficacy of belzutifan was similar between the RP2D of 120-mg dose and the 200-mg dose and was consistent with prior reports of antitumor activity in ccRCC. Safety at both doses was consistent with the known safety profile of belzutifan. These results further support 120 mg QD as the preferred dose for belzutifan.
Clinical trial identification
NCT04489771.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Shane Walton and Robert Steger of ApotheCom (Yardley, PA). Funding for this assistance was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
N. Agarwal: Financial Interests, Personal, Advisory Role: Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, Seattle Genetics; Financial Interests, Institutional, Research Funding: Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, BMS, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neole. J. Brugarolas: Financial Interests, Personal and Institutional, Licencing Fees or royalty for IP: UT Southwestern Medical Center. P. Ghatalia: Non-Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Funding: Oryzon, Merck. S. George: Financial Interests, Institutional, Research Grant: Pfizer, Merck, Agensys, Novartis, BMS, Bayer, Eisai, Seattle Genetics/Astellas, Calithera Biosciences, Corvus Pharmaceuticals, Surface Oncology, Exelixis, Aravive, Aveo, Gilead Sciences; Financial Interests, Personal, Advisory Board: BMS, Bayer, Pfizer, Exelixis, Corvus Pharmaceuticals, Sanofi, EMD Serono, Seattle Genetics/Astellas, Eisai, Merck, Aveo, QED Therapeutics; Financial Interests, Institutional, Sponsor/Funding: Pfizer, Merck, Agensys, Novartis, BMS, Bayer, Eisai, Seattle Genetics/Astellas, Calithera Biosciences, Corvus Pharmaceuticals, Surface Oncology, Exelixis, Aravive, Aveo, Gilead Sciences. J.B.A.G. Haanen: Financial Interests, Institutional, Research Grant: Amgen, BioNTech, BMS, MSD, Neogene Tx, Novartis; Financial Interests, Personal and Institutional, Advisory Board: Achilles Tx, CureVac, Imcyse, Instil Bio, Iovance Bio, Ipsen, Merck, Molecular Partners, PokeAcell, Pfizer, Sanofi, Scenic, T-Knife, TRV. H.P. Gurney: Financial Interests, Personal, Advisory Board: BMS AstraZeneca Astella Merck Serono MSD Ipsen Pfizer. R. Ravilla: Financial Interests, Personal, Speaker’s Bureau: Janssen, Exelixis, BMS; Financial Interests, Personal, Advisory Board: Seagen/Astellas. A.A.M. Van der Veldt: Financial Interests, Institutional, Advisory Board: BMS, MSD, Pfizer, Merck, Roche, Novartis, Sanofi, Ipsen, Eisai, Pierre Fabre. B. Beuselinck: Financial Interests, Institutional, Advisory Board: MSD, BMS, Ipsen; Financial Interests, Institutional, Expert Testimony: MSD; Financial Interests, Institutional, Speaker’s Bureau: BMS, Pfizer, Ipsen; Financial Interests, Institutional, Research Grant: BMS. M. Tuthill: Non-Financial Interests, Personal, Advisory Board: Vaccitech UK Limited; Financial Interests, Personal, Advisory Board: Merck & Co., Inc., Novartis, AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Merck & Co., Inc., AstraZeneca; Financial Interests, Personal, Principal Investigator: Merck & Co., Inc., Novartis; Financial Interests, Personal, Research Grant: AstraZeneca. D. Vaena: Financial Interests, Personal, Advisory Board: Seattle Genetics, Bayer, Eisai, BMS, EMD Serono, Exelixis, Janssen; Non-Financial Interests, Institutional, Principal Investigator: Compugen, OBI Pharma, Merck, Atreca, NGM Bio, BMS, Genentech. F. Zagouri: Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Eli Lilly, Merck, Novartis, MSD, Pfizer, Genesis Pharma, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, Daiichi Sankyo, Eli Lilly, Merck, Novartis, MSD, Pfizer, Genesis Pharma, Roche. Y. Liu: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck; Financial Interests, Personal, Sponsor/Funding: Merck. R. Perini: Financial Interests, Personal, Full or part-time Employment: Merck Sharpe and Dohme; Financial Interests, Personal, Stocks/Shares: Merck Sharpe and Dohme. J.R. Merchan: Financial Interests, Personal and Institutional, Advisory Board: Merck; Financial Interests, Institutional, Principal Investigator: Merck, Sillajen, Eisai, Exelixis, Imugene, Seattle Genetics, Peloton Therapeutics, Genentech, Rubius Therapeutics, Replimune; Financial Interests, Institutional, Research Grant: Sillajen. M.B. Atkins: Financial Interests, Personal and Institutional, Advisory Board: Merck, BMS; Financial Interests, Personal and Institutional, Research Grant: Merck, BMS; Financial Interests, Personal, Advisory Board: Exelixis, Eisai, Genentech-Roche. All other authors have declared no conflicts of interest.
Resources from the same session
LBA87 - Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
Presenter: Toni Choueiri
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
Presenter: Laurence Albiges
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA87, LBA88 and 1881O
Presenter: Lisa Pickering
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Webcast
1882O - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study
Presenter: Xinan Sheng
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1882O
Presenter: Astrid Van der Veldt
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Genitourinary tumours, non-prostate
Resources:
Webcast